Data presented today at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE? (infliximab) over two years experienced significant improvement in spinal mobility.
Treatment with belimumab resulted in a sustained improvement of systemic lupus erythematosus disease activity in 46 percent of patients at week 52, according to a novel combined responder index in results presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Findings reported today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, reveal a treatment disparity between female and male patients with rheumatoid arthritis. Data from a study at the Karolinska Institute, Sweden, show that women receive anti-TNFs — very effective but expensive modern medications against this disease — at a higher perceived level of disease activity, and when they are reporting more severe pain than their male counterparts.
Thirty-six percent of patients with refractory systemic lupus erythematosus remain well after undergoing B-cell depletion therapy without needing further standard immunosuppressive agents, according to a study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
In just two years, patients with hand osteoarthritis experienced a significant increase in pain and functional limitations, according to new data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. Statistically significant radiological progression was also detected in 20 percent of subjects.
In the first international “map of rheumatoid arthritis,” spanning Europe and beyond, significant national differences in RA severity can be directly traced to national economics, most notably health expenditure, as exposed today by data from the QUEST-RA Study presented at EULAR 2007, the Annual Congress of the European League Against Rheumatism, Barcelona, Spain.
Two years or more of oral steroid treatment decreases the risk of rheumatoid arthritis related lymphoma, according to data presented today at EULAR 2007, the Annual European Congress of Rheumatology, in Barcelona, Spain. Furthermore, these effects were found regardless of when in the course of the disease the steroids were first administered. However, these beneficial effects were not observed if the steroids were taken for less than a two-year period.
Early treatment with a combination of methotrexate and infliximab may be effective as remission induction therapy and alter the course of early rheumatoid arthritis, according to data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
The global obesity epidemic was issued with a further health warning today — that obesity exacerbates the quality of life of patients with rheumatoid arthritis. New data presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, shows that RA in obese patients is associated with worse quality of life outcomes on four key levels: pain, fatigue, physical function and overall utility scores.
Taking X-rays of the semi-flexed knee is the most accurate way of evaluating structural damage in patients with knee osteoarthritis according to results presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.